Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1492383 | 0.99 | CASP3 (0.46) | CASP3MAPTKDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL1492230 | 0.89 | LMNA (0.57) | MAPTKDM4ECYP1A2SMN1; SMN2NPC1 | |
| SCHEMBL18955943 | 0.86 | GABRA2 (0.51) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL19643804 | 0.86 | ALDH1A1 (0.57) | MAPTKDM4ECYP1A2MEN1KMT2A | |
| SCHEMBL1492332 | 0.85 | SMN1; SMN2 (0.52) | CASP3MAPTKDM4ECYP1A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1492314 | 0.84 | SMN1; SMN2 (0.51) | CASP3MAPTKDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL1492270 | 0.79 | KMT2A (0.42) | CASP3MAPTKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL1492360 | 0.78 | UCHL1 (0.42) | MAPTKDM4ECYP1A2SMN1; SMN2LMNA | |
| SCHEMBL1492408 | 0.78 | ALDH1A1 (0.46) | MAPTKDM4ECYP1A2SMN1; SMN2MEN1 | |
| SCHEMBL19661208 | 0.77 | NPC1 (0.48) | MAPTKDM4ESMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475660-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | PRKAB1, PRKAG1, PRKAB2 | CASP3 2931/4885MAPT 1823/4885KDM4E 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.